Literature DB >> 18541802

Vitamin D-dependent rickets as a possible risk factor for multiple sclerosis.

Øivind Torkildsen1, Per Morten Knappskog, Harald I Nyland, Kjell-Morten Myhr.   

Abstract

BACKGROUND: Vitamin D-dependent rickets type I (VDDR I) (OMIM 264700) is a rare hereditary condition caused by a mutation in CYP27B1. Vitamin D is emerging as an important risk factor for susceptibility to multiple sclerosis (MS), but there have been no studies on the possible association between hereditary rickets and this disease.
OBJECTIVE: To investigate the association between VDDR I and MS.
DESIGN: Case studies.
SETTING: Haukeland University Hospital, Bergen, Norway. PATIENTS: Three patients in 2 families with a co-occurrence of VDDR I and MS.
RESULTS: All 3 patients had VDDR I verified by genetic testing and fulfilled the Poser criteria for MS. Two of the patients have undergone magnetic resonance imaging, which confirmed the diagnosis of long-lasting MS.
CONCLUSIONS: Vitamin D-dependent rickets type I is a very uncommon genetic subtype of rickets. We have identified 3 patients with this disease who later developed MS. We propose that VDDR I and possibly other hereditary rickets mutations that influence vitamin D metabolism could be risk factors for this disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18541802     DOI: 10.1001/archneur.65.6.809

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  14 in total

Review 1.  Multiple sclerosis, vitamin D, and HLA-DRB1*15.

Authors:  Lahiru Handunnetthi; Sreeram V Ramagopalan; George C Ebers
Journal:  Neurology       Date:  2010-06-08       Impact factor: 9.910

2.  Contribution of vitamin D insufficiency to the pathogenesis of multiple sclerosis.

Authors:  Charles Pierrot-Deseilligny; Jean-Claude Souberbielle
Journal:  Ther Adv Neurol Disord       Date:  2013-03       Impact factor: 6.570

3.  No evidence of association between mutant alleles of the CYP27B1 gene and multiple sclerosis.

Authors:  Maria Ban; Stacy Caillier; Inger-Lise Mero; Kjell-Morten Myhr; Elisabeth G Celius; Jan Aarseth; Øivind Torkildsen; Hanne F Harbo; Jorge Oksenberg; Stephen L Hauser; Stephen Sawcer; Alastair Compston
Journal:  Ann Neurol       Date:  2013-02-26       Impact factor: 10.422

Review 4.  The initiation and prevention of multiple sclerosis.

Authors:  Alberto Ascherio; Kassandra L Munger; Jan D Lünemann
Journal:  Nat Rev Neurol       Date:  2012-10-09       Impact factor: 42.937

5.  Study of Vitamin D Receptor Gene Polymorphism (FokI, TaqI and ApaI) Among Prostate Cancer Patients in North India.

Authors:  Pankaj Ramrao Kambale; Deepa Haldar; B C Kabi; Kalpana Pankaj Kambale
Journal:  J Clin Diagn Res       Date:  2017-06-01

6.  Hospital admissions for vitamin D related conditions and subsequent immune-mediated disease: record-linkage studies.

Authors:  Sreeram V Ramagopalan; Raph Goldacre; Giulio Disanto; Gavin Giovannoni; Michael J Goldacre
Journal:  BMC Med       Date:  2013-07-25       Impact factor: 8.775

Review 7.  Vitamin D Actions on CD4(+) T Cells in Autoimmune Disease.

Authors:  Colleen Elizabeth Hayes; Shane L Hubler; Jerott R Moore; Lauren E Barta; Corinne E Praska; Faye E Nashold
Journal:  Front Immunol       Date:  2015-03-18       Impact factor: 7.561

8.  A "candidate-interactome" aggregate analysis of genome-wide association data in multiple sclerosis.

Authors:  Rosella Mechelli; Renato Umeton; Claudia Policano; Viviana Annibali; Giulia Coarelli; Vito A G Ricigliano; Danila Vittori; Arianna Fornasiero; Maria Chiara Buscarinu; Silvia Romano; Marco Salvetti; Giovanni Ristori
Journal:  PLoS One       Date:  2013-05-16       Impact factor: 3.240

Review 9.  Environmental risk factors for multiple sclerosis: a review with a focus on molecular mechanisms.

Authors:  Cullen O'Gorman; Robyn Lucas; Bruce Taylor
Journal:  Int J Mol Sci       Date:  2012-09-18       Impact factor: 6.208

10.  Can we prevent or treat multiple sclerosis by individualised vitamin D supply?

Authors:  Jan Dörr; Andrea Döring; Friedemann Paul
Journal:  EPMA J       Date:  2013-01-29       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.